For information about COVID-19, including symptoms and prevention, please read our COVID-19 patient guide. If you need to see your provider, please contact us to see if a Video Visit is right for you. Please also consider supporting Weill Cornell Medicine’s efforts against the pandemic.
Department of Anesthesiology

You are here

Considerations for evaluating the use of intrathecal drug delivery in the oncologic patient.

TitleConsiderations for evaluating the use of intrathecal drug delivery in the oncologic patient.
Publication TypeJournal Article
Year of Publication2014
AuthorsGulati A, Puttanniah V, Hung J, Malhotra V
JournalCurr Pain Headache Rep
Date Published2014 Feb
KeywordsAnalgesics, Opioid, Evidence-Based Medicine, Female, Humans, Infusion Pumps, Implantable, Injections, Spinal, Male, Neoplasms, Pain, Intractable, Patient Selection

While the majority of cancer pain patients are successfully managed with conservative medical management, some patients may suffer from intractable pain or intolerable side effects. The implantation of an intrathecal drug delivery system offers many advantages to improve both analgesia and side effect profile. Practitioners may decide to proceed toward implantation after appropriate patient selection, and, when applicable, a suitable trial for the device. Once implantation is completed, multiple medication combinations may be used to optimize the therapeutic benefit of the device. We describe a stepwise paradigm to implement an intrathecal drug delivery program in the cancer pain population.

Alternate JournalCurr Pain Headache Rep
PubMed ID24407749